相关实验视频

Updated: Jul 29, 2025

Orthotopic Hind Limb Transplantation in the Mouse

Orthotopic Hind Limb Transplantation in the Mouse

Published on: February 12, 2016

诱导的多能干细胞衍生的造血干细胞和原始细胞诱导混合的仿真和特定于供体的全移植耐受性

Tomoki Murata¹, Naoki Hama¹, Tomoki Kamatani¹

¹Division of Immunobiology, Institute for Genetic Medicine, Hokkaido University, Sapporo, Hokkaido, Japan.

American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons

|May 27, 2023

概括

诱导多能干细胞衍生出血造干细胞/原始细胞 (iHSPCs) 可以诱导异构移植中的耐受性. 这项研究表明,iHSPCs可以建立混合嵌合体并防止移植拒绝,为干细胞治疗提供了一种新的策略.

科学领域:

免疫学免疫学免疫学
再生医学是一种再生医学.
干细胞生物学干细胞生物学

背景情况:

全基因移植面临着免疫排斥的挑战,即使是主要的组织相容性复合体匹配.
轻微的抗原不匹配被认为是移植拒绝的重要风险因素.
与供体造血干细胞/原生细胞 (HSPCs) 混合合体可以在器官移植中诱导耐受性,但其与iPSC衍生的HSPCs (iHSPCs) 的疗效尚不清楚.

研究的目的:

为了调查iHSPCs是否可以诱导在异种环境中的异种移植耐受性.
探索iHSPCs在建立混合嵌合体和预防免疫排斥方面的潜力.

主要方法:

使用血液生成转录因子Hoxb4和Lhx2.2,有效扩展具有长期血液生成重定位潜力的iHSPCs.
使用扩展的iHSPCs在异种接受者中生成血液构造的仿真体.
在小鼠皮肤和iPSC移植模型中评估allograft耐受性诱导.

主要成果:

Hoxb4和Lhx2有效地扩展了具有c-Kit+Sca-1+Lineage表型和长期重新填充潜力的iHSPCs.
这些iHSPCs成功地在异种接受者中形成了血液构造的嵌合体.
在小鼠的皮肤和iPSCs的异构移植证明了通过iHSPCs调解的耐受性诱导.

结论:

从iPSC衍生的HSPCs (iHSPCs) 可以在异种接收者中建立混合的仿真.
iHSPCs可以在皮肤和iPSC移植中诱导供体特异性耐受性,这表明潜在的治疗应用.
这项研究提供了使用iHSPCs在异种iPSC基移植中诱导耐受性的基本概念.

关键词:

在iPS的手机上,iPS是iPS的手机.混合的奇幻主义.耐受性诱导的诱导耐受性

更多相关视频

Detection of Residual Donor Erythroid Progenitor Cells after Hematopoietic Stem Cell Transplantation for Patients with Hemoglobinopathies

Detection of Residual Donor Erythroid Progenitor Cells after Hematopoietic Stem Cell Transplantation for Patients with Hemoglobinopathies

Published on: September 6, 2017

Bone Marrow Transplantation Procedures in Mice to Study Clonal Hematopoiesis

Bone Marrow Transplantation Procedures in Mice to Study Clonal Hematopoiesis

Published on: May 26, 2021

相关概念视频

Bone Marrow Sampling and Transplants

Bone Marrow Sampling and Transplants

Bone marrow transplant is a potential cure for several diseases, including cancer and specific genetic disorders. Notably, this procedure is applicable for patients suffering from aplastic anemia, certain types of leukemia, severe combined immunodeficiency disease (SCID), Hodgkin's disease, non-Hodgkin's lymphoma, multiple myeloma, thalassemia, sickle-cell disease, and certain cancers.
The transplant begins with high doses of chemotherapy and radiation treatment, which aim to destroy...

Multipotency of Hematopoietic Stem Cells

Multipotency of Hematopoietic Stem Cells

The hematopoietic stem cells or HSCs are multipotent, meaning they can differentiate and give rise to all blood and immune cells. HSCs are maintained in the quiescent stage until an external stimulus initiates their differentiation. The multipotent HSCs exist as two heterogeneous populations, long-term repopulating cells (LTRC) and short-term repopulating cells (STRC). The two HSC populations have different surface markers or receptors and are classified based on quiescence and long-term...

iPS Cell Differentiation

iPS Cell Differentiation

The ability of induced pluripotent stem cells or iPSCs to differentiate into most body cell types has stimulated repair and regenerative medicine research over the past few decades. iPSC-derived blood cells, hepatocytes, beta islet cells, cardiomyocytes, neurons, and other cell types can repair injuries or regenerate damaged tissue in diseases such as diabetes and neurodegenerative disorders.

Tissue Transplantation

Tissue Transplantation

Tissue transplantation is a significant medical procedure involving the transfer of cells, tissues, or organs from a donor to a recipient, with the primary aim of restoring lost functions. This procedure is crucial in treating a broad spectrum of diseases, including kidney diseases, liver failure, heart disease, and certain types of cancers.
The Biology of Tissue Transplantation
The biology of tissue transplantation hinges on the Major Histocompatibility Complex (MHC) molecules. These molecules...